Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • News & Views
  • Published:

ALZHEIMER DISEASE

Primary fatty amides are potential plasma biomarkers for AD

Nature Reviews Neurology volume 15, pages 498–499 (2019)Cite this article

Subjects

A new study has found that levels of primary fatty amides in plasma correlate with amyloid-β pathology and other Alzheimer disease (AD)-related phenomena. In addition to identifying potential plasma biomarkers for AD, the findings suggest new avenues for investigation into the early stages of AD.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Hansson, O. et al. Association between CSF biomarkers and incipient Alzheimer’s disease in patients with mild cognitive impairment: a follow-up study. Lancet Neurol. 5, 228–234 (2006).

    Article  CAS  Google Scholar 

  2. Palmqvist, S. et al. Earliest accumulation of β-amyloid occurs within the default-mode network and concurrently affects brain connectivity. Nat. Commun. 8, 1214 (2017).

    Article  Google Scholar 

  3. Villeneuve, S. et al. Existing Pittsburgh compound-B positron emission tomography thresholds are too high: statistical and pathological evaluation. Brain J. Neurol. 138, 2020–2033 (2015).

    Article  Google Scholar 

  4. Ossenkoppele, R. et al. Discriminative accuracy of [18F]flortaucipir positron emission tomography for Alzheimer disease versus other neurodegenerative disorders. JAMA 320, 1151–1162 (2018).

    Article  CAS  Google Scholar 

  5. Nakamura, A. et al. High performance plasma amyloid-β biomarkers for Alzheimer’s disease. Nature 554, 249–254 (2018).

    Article  CAS  Google Scholar 

  6. Zetterberg, H. et al. Plasma tau levels in Alzheimer’s disease. Alzheimers Res. Ther. 5, 9 (2013).

    Article  CAS  Google Scholar 

  7. Mattsson, N. et al. Association of plasma neurofilament light with neurodegeneration in patients with Alzheimer disease. JAMA Neurol. 74, 557–566 (2017).

    Article  Google Scholar 

  8. Kim, M. et al. Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer’s Disease biomarker discovery cohort. Alzheimers Dement. 15, 817–827 (2019).

    Article  Google Scholar 

  9. Mapstone, M. et al. Plasma phospholipids identify antecedent memory impairment in older adults. Nat. Med. 20, 415–418 (2014).

    Article  CAS  Google Scholar 

  10. Casanova, R. et al. Blood metabolite markers of preclinical Alzheimer’s disease in two longitudinally followed cohorts of older individuals. Alzheimers Dement. 12, 815–822 (2016).

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Clinical Memory Research Unit, Department of Clinical Sciences, Lund University, Malmö, Sweden

    Niklas Mattsson & Oskar Hansson

  2. Wallenberg Centre for Molecular Medicine, Lund University, Lund, Sweden

    Niklas Mattsson

Authors
  1. Niklas Mattsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Oskar Hansson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Oskar Hansson.

Ethics declarations

Competing interests

The authors declare no competing interests.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Mattsson, N., Hansson, O. Primary fatty amides are potential plasma biomarkers for AD. Nat Rev Neurol 15, 498–499 (2019). https://doi.org/10.1038/s41582-019-0229-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/s41582-019-0229-6

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research